Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection
Open Access
- 30 August 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 18 (12) , 1656-1663
Abstract
Patients with malignant gliomas present with variation in neurocognitive function (NCF) not attributable to lesion size or location alone. A potential contributor is the rate at which tumors grow, or “lesion momentum.” Isocitrate dehydrogenase 1 wild type (IDH1-WT) are more proliferative and aggressive than IDH1-mutant (IDH1-M) tumors. We hypothesized that patients with IDH1-WT would exhibit worse NCF than patients with IDH1-M tumors. Comprehensive NCF testing was completed in 119 patients with malignant glioma prior to surgical resection. IDH1 status was determined with immunohistochemistry and sequencing. Rates of impairment and mean test performances were compared by IDH1. NCF impairment was significantly more frequent in patients with IDH1-WT tumors in memory, processing speed, visuoconstruction, language, executive functioning, and manual dexterity. Mean performances of patients with IDH1-WT were also significantly lower than those with IDH1-M tumors on measures of learning and memory, processing speed, language, executive functioning, and dexterity. Lesion volume was not statistically different between IDH1-WT and IDH1-M tumors. Tumor and lesion volume on T1-weighted and fluid attenuated inversion recovery MRI were significantly associated with most NCF tests in patients with IDH1-WT, but only significantly associated with a single measure in patients with IDH1-M tumors. Patients with IDH1-WT show reduced NCF compared with those with IDH1-M malignant gliomas. Lesion volume is inversely associated with NCF for patients with IDH1-WT, but not IDH1-M tumors. These findings are consistent with the hypothesis that patients with IDH1-WT tumors present with more severe NCF impairment due to greater lesion momentum, which may impede compensatory neuroplasticity and cerebral reorganization.Keywords
Funding Information
- National Institutes of Health
- National Institute of Nursing Research (R01NR014195)
- National Cancer Institute (P50CA165962)
- Burroughs Wellcome Fund
This publication has 36 references indexed in Scilit:
- IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in gliomaNeuro-Oncology, 2013
- Isocitrate dehydrogenase 1: what it means to the neurosurgeonJournal of Neurosurgery, 2013
- Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of OriginJournal of Clinical Oncology, 2011
- Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular MetabolismJNCI: Journal of the National Cancer Institute, 2010
- Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma NetworkJournal of Clinical Oncology, 2009
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in GliomasJournal of Clinical Oncology, 2009
- IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomasNeuro-Oncology, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Does brain tumor histology influence cognitive function?Neuro-Oncology, 2003